vsport体育官网入口
What we do
Improving people’s lives and health outcomes by focusing on areas of high unmet medical need, we are accelerating our momentum and rapidly boosting our pipeline to bring the full potential of our innovative medicines to patients.
Learn morevsport体育官网入口
Oncology
people die from cancer every year, making it a leading global killer
Rare Diseases
people globally are living with a rare disease, most of whom have no approved treatment
Neuroscience
people worldwide live with spasticity, yet access to treatment remains limited
Underserved Population
of rare diseases begin in childhood yet most go undiagnosed or untreated
Our strategy has been instrumental in making us a leader in our field. Our global presence, resources, expertise and strong track record commercializing our medicines are resulting in a real impact for people living with high unmet medical needs. We’re leveraging the full force of Ipsen’s infrastructure, innovation and passion to develop new therapies and valuable collaborations.
vsport体育官网入口
Find out what’s been going on at Ipsen of late – with press releases, trending stories, events, and more.
30 July 2026
Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance
22 July 2026
Ipsen completes acquisition of Memo Therapeutics AG, adding first-in-class asset to Ipsen’s Rare Disease pipeline
13 July 2026
IQIRVO? demonstrates statistically significant improvement in ALP normalization in patients with PBC in Phase IIIb…
09 July 2026
Dysport? is the first botulinum toxin to achieve positive topline Phase III results in both…
01 July 2026
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
29 June 2026
Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline
28 May 2026
New late-breaking data reinforces IQIRVO?’s impact on ALP, fatigue and pruritus in PBC
19 May 2026
Ipsen announces late-breaking data from first head-to-head study comparing Dysport? and Botox? in adults with…
15 May 2026
Late-breaking data from EASL reinforces IQIRVO’s impact on ALP reduction with fatigue and pruritus improvement…
14 May 2026
Ipsen unveils corabotase, a first-in-class recombinant neuroinhibitor, RNI?, at the SCALE Symposium
vsport体育官网入口
Ipsen focuses on three key therapeutic areas, leveraging all our resources to help patients with unmet medical needs.
Oncology
Ipsen has been working in oncology since 1986, and now has a portfolio that includes treatments for neuroendocrine tumor (NETs), and cancers of the kidney, liver, pancreas, thyroid, prostate and breast.
Rare Disease
Ninety-four percent of rare medical conditions still have no treatment. We are committed to finding treatments for extremely rare bone diseases and disorders, growth disorders, rare cancers, rare liver disease and rare neurogenetic disorders.
Neuroscience
Ipsen draws on 30 years of expertise in toxins and neuroscience research to support children and adults suffering from debilitating and degenerative neurological conditions.
